faruk capan

Digital pharma, social media, mhealth, marketing, mobile, search, innovator

[faruk capan @farukcapan]

Continued collaboration across government, healthcare providers, and the pharmaceutical industry will be essential to addressing persistent challenges and delivering lasting improvements for patients.

[faruk capan @farukcapan]

The TrumpRX announcement confirmed what I’ve long thought about this administration: they’re willing to reassess long-standing assumptions that have shaped the industry for decades.

[faruk capan @farukcapan]

The MAHA movement reflects a broader willingness to challenge the status quo. While there may be areas of disagreement, its emphasis on structural reform is worth serious consideration. Efforts to improve affordability and access should remain focused on measurable patient outcomes rather than ideology.

[faruk capan @farukcapan]

AI will not replace doctors. But doctors using AI will replace doctors not using AI.

Same for healthcare policy: Measurable outcomes should replace ideology. It’s time for real patient-focused care that puts Americans first.

[faruk capan @farukcapan]

The MAHA Movement provides an opportunity for real change. It provides an opening to question the dogma that has dominated the pharmaceutical industry for my entire career.

My hope is that we are able to take advantage of this moment to create real change on behalf of our patients.

[faruk capan @farukcapan]

We talked about what I’ve learned throughout my career, with the hope that they’ll be able to use my ideas to build a more patient-centered healthcare experience.

[faruk capan @farukcapan]

I was excited to be on Capitol Hill last week, meeting with lawmakers and their staffs about the critical opportunities the MAHA movement provides to create real change within the healthcare system.

[faruk capan @farukcapan]

I’ve shared my thoughts on how we can work together toward a more sustainable solution in my latest piece for RealClearHealth. https://t.co/UQB2X0vRGF

[faruk capan @farukcapan]

Throughout my 30-year career, I’ve seen how our drug-pricing system has become increasingly complex. Despite good intentions, the current model often prioritizes supply chain interests over the people who actually need the medicine.

[faruk capan @farukcapan]

Stakeholders, from pharma leaders to PBMs and government officials, recognize these flaws but refuse to implement change because it requires a major operating shift. We have an opportunity to move beyond surface-level discussion and address the underlying structure of the system.

[faruk capan @farukcapan]

Both Pharma and the MAHA movement have oversimplistic views of the current system.

Here’s the truth: we have incredible medicines that save lives and a pricing system that exploits patients. We have vital vaccines that prevent disease, and also legitimate questions about overmedicalization. Adults should be able to hold both perspectives.

[faruk capan @farukcapan]

Proud to have an op-ed reflecting on my experience at the MAHA Summit published earlier this week in @InsideSourcesDC.

If you’re interested in reading more about my experience, please click here: https://t.co/y8zph2fMXC

[faruk capan @farukcapan]

I didn’t agree with everything that I heard, but I respect what I saw: people who believe healthcare can be better and want to make that happen.

[faruk capan @farukcapan]

On November 12, I was proud to attend the MAHA Summit. Throughout my career, I’ve proudly stayed nonpartisan. That independence gives me the freedom to focus on one thing: fostering dialogue that actually helps patients.

[faruk capan @farukcapan]

We share common goals, such as modernizing the FDA, leveraging AI to reduce the bureaucracy that frequently delays patient care, increasing transparency in drug development and safety concerns, bringing prevention and longevity into mainstream care, and giving patients more agency.